GSK plc American Depositary Shares (Each representing two Ordinary Shares)
GSK · NYSE
Analyst Consensus
Hold
Analyst Ratings Synthesis
The supplied consensus is Hold across 11 analysts, with a mean price target of $54. Low and high targets are unavailable, so the degree of target clustering and the spread cannot be assessed. No named analyst is identified as the most or least bullish, and the evidence contains no target or rating revisions during the week. It also does not provide the substantive disagreement behind the target distribution. The mean target stands $2.47 above the supplied ending price of $51.53, but that comparison does not reveal how individual analysts differ or whether views changed in response to GSK’s Relation Therapeutics collaboration.
- Medicus Appoints Mehmud CEO Of UK Unit Antev, Replacing Interim CEO Kholi; Stock Up
- Weekly Buzz:CIPLA, VTRS Win FDA Nod; BSX Cuts Jobs; ARGX Snaps Up FBRX; JNJ, GSK Strike Deals
- IONS Beats Q2 Earnings & Sales Estimates, Reiterates '26 Outlook
- GSK Strikes $110M AI Deal With Relation Therapeutics To Boost Early Pipeline
- GSK Strikes $100M AI Deal With Relation Therapeutics To Boost Early Pipeline
Rating Actions
No individual rating actions have been captured for GSKyet. Consensus figures above come from Nasdaq's aggregate feed.
